Selumetinib Shrinks NF1-Plexiform Neurofibromas in Adults, Too

By News Health
2 months Ago

(MedPage Today) — CHICAGO — Selumetinib (Koselugo) significantly improved response rates in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas, the phase III KOMET trial showed.
After 16 cycles…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115874

Author :

Publish date : 2025-06-03 15:43:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Major Medical Groups Pushed Out of Role Supporting CDC's Vaccine Advisors

'It's Gonna Be (Ly)me': Justin Timberlake Brings Attention, Awareness to Disease

ACOG No Longer Accepting Federal Funding, Citing Policy Disputes

States Sue Trump, Say Targeting of Hospitals Over Gender Care in Minors Is Unlawful

Time Your Meals, Tune Your Metabolism

Novel Eye Drops for Age-Related Blurry Vision Win FDA Approval